Insights

This Growth Stock Is Raising Guidance Despite Multiple Headwinds

The months ahead are going to be full of uncertainty for the economy. The war in Ukraine, rising interest rates, and inflation are just some of the headwinds that many global businesses are facing these days. 
However, one healthcare company that sees growth on the horizon is Thermo Fisher Scientific (NYSE: TMO). Not only is it not too concerned about these obstacles, but it also recently raised its guidance for the year. 
Image source: Getty Images.

Thermo Fisher expects 8% revenue growth in 2022
On its first-quarter earnings call last month, Thermo Fisher’s CEO Marc Casper said that the company was raising its guidance for the year by $450 million. For 2022, the business now expects to bring in $42.45 billion in sales — an 8% increase from 2021. Just a few months earlier, in February, the company said it was projecting 2022 revenue to come in at $42 billion. And at the time, that was already a $1.5 billion increase in its guidance.
Even though $450 million may sound like a relatively modest increase for a company that makes over $40 billion in revenue, combined with the February increase, that’s nearly $2 billion more that Thermo Fisher is expecting to generate since the start of the year. It’s a positive sign to investors that the company is confident enough just to issue guidance for the year (many businesses have simply avoided making any forecasts), let alone increase it. And the company could perform even better than this, as the guidance “incorporates the expected impact of the recent macroeconomic dynamics.”
Why is the company so bullish?
What has Thermo Fisher optimistic is that it has been gaining market share, and its recent acquisition, PPD, has also been contributing and helping the business grow. It was only this past December that Thermo Fisher closed on its $17.4 billion acquisition of clinical research services company PPD. It can take some time to see how a new acquisition integrates with the existing business — and obviously, the early results have been promising enough to justify an increase in guidance. Not only was revenue in its most recent quarter (the period ending April 2) $1 billion better than the company’s previous guidance, but its adjusted per-share profit was also $0.84 higher.
But it’s more than just recent results that have the company optimistic about the year. Here’s a more detailed breakdown of what’s behind Thermo Fisher’s latest guidance increase:
Reason
Revenue Impact
Higher COVID-19 testing revenue
$350 million
Improved outlook for the core business
$300 million
Change in foreign exchange
($200 million)
Total change in guidance
$450 million
Source: Company earnings calls. Table by author.
Thermo Fisher also noted that PPD will generate $6.7 billion in revenue for the year, which represents core organic growth of 11%, which is also ahead of earlier guidance.
Thermo Fisher is a stock you can buy and hold for decades
Although Thermo Fisher’s stock is down 21% this year (worse than the S&P 500’s decline of 16%), it’s still a terrific long-term buy. Over the years, the company has grown via acquisitions and successfully integrated many businesses into its operations, with PPD being just the latest. The company knows how to efficiently grow, and that’s a great sign for long-term investors.
And historically, Thermo Fisher has been a market-beating stock, with its 5-year returns of 207% eclipsing the S&P 500’s gains of just 68% during that period. In all likelihood, given the continued growth and stability that the stock offers, Thermo Fisher will continue to outperform the broader markets over the long haul. And that’s what makes it a great stock to load up on today.
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Thermo Fisher Scientific. The Motley Fool has a disclosure policy. –

The months ahead are going to be full of uncertainty for the economy. The war in Ukraine, rising interest rates, and inflation are just some of the headwinds that many global businesses are facing these days. 

However, one healthcare company that sees growth on the horizon is Thermo Fisher Scientific (NYSE: TMO). Not only is it not too concerned about these obstacles, but it also recently raised its guidance for the year. 

Image source: Getty Images.

Thermo Fisher expects 8% revenue growth in 2022

On its first-quarter earnings call last month, Thermo Fisher’s CEO Marc Casper said that the company was raising its guidance for the year by $450 million. For 2022, the business now expects to bring in $42.45 billion in sales — an 8% increase from 2021. Just a few months earlier, in February, the company said it was projecting 2022 revenue to come in at $42 billion. And at the time, that was already a $1.5 billion increase in its guidance.

Even though $450 million may sound like a relatively modest increase for a company that makes over $40 billion in revenue, combined with the February increase, that’s nearly $2 billion more that Thermo Fisher is expecting to generate since the start of the year. It’s a positive sign to investors that the company is confident enough just to issue guidance for the year (many businesses have simply avoided making any forecasts), let alone increase it. And the company could perform even better than this, as the guidance “incorporates the expected impact of the recent macroeconomic dynamics.”

Why is the company so bullish?

What has Thermo Fisher optimistic is that it has been gaining market share, and its recent acquisition, PPD, has also been contributing and helping the business grow. It was only this past December that Thermo Fisher closed on its $17.4 billion acquisition of clinical research services company PPD. It can take some time to see how a new acquisition integrates with the existing business — and obviously, the early results have been promising enough to justify an increase in guidance. Not only was revenue in its most recent quarter (the period ending April 2) $1 billion better than the company’s previous guidance, but its adjusted per-share profit was also $0.84 higher.

But it’s more than just recent results that have the company optimistic about the year. Here’s a more detailed breakdown of what’s behind Thermo Fisher’s latest guidance increase:

Reason
Revenue Impact
Higher COVID-19 testing revenue
$350 million
Improved outlook for the core business
$300 million
Change in foreign exchange
($200 million)
Total change in guidance
$450 million

Source: Company earnings calls. Table by author.

Thermo Fisher also noted that PPD will generate $6.7 billion in revenue for the year, which represents core organic growth of 11%, which is also ahead of earlier guidance.

Thermo Fisher is a stock you can buy and hold for decades

Although Thermo Fisher’s stock is down 21% this year (worse than the S&P 500‘s decline of 16%), it’s still a terrific long-term buy. Over the years, the company has grown via acquisitions and successfully integrated many businesses into its operations, with PPD being just the latest. The company knows how to efficiently grow, and that’s a great sign for long-term investors.

And historically, Thermo Fisher has been a market-beating stock, with its 5-year returns of 207% eclipsing the S&P 500’s gains of just 68% during that period. In all likelihood, given the continued growth and stability that the stock offers, Thermo Fisher will continue to outperform the broader markets over the long haul. And that’s what makes it a great stock to load up on today.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Thermo Fisher Scientific. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!